Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYD dengue vaccine
- Development stage
- Phase 2
- Lead developer
- Parent
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
CYD dengue vaccine is a tetravalent live-attenuated recombinant vaccine developed by Sanofi Pasteur. It is designed to prevent symptomatic virologically-confirmed dengue cases by eliciting an immune response against all four dengue virus serotypes (1, 2, 3, and 4). The vaccine has been studied in various dose schedules and booster regimens to assess its immunogenicity and safety in healthy subjects across different age groups and geographical regions.
- Other names
- ChimeriVax Tetravalent Dengue Vaccine
Beyond the preview
Go deeper on CYD dengue vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYD dengue vaccine.